JAK1/JAK2/ACVR1 inhibitor
Momelotinib (Specialist drug)
Brand names: Omjjara
Adult dose
Dose: Specialist initiation only — refer to BNF/SmPC
Route: PO
Frequency: OD
Clinical pearls
- Myelofibrosis with anaemia; specialist haematology — preserves Hb compared to ruxolitinib
Contraindications
- See SmPC
Side effects
- Thrombocytopenia
- Hepatotoxicity
- Increased infection risk
- Peripheral neuropathy
- Hypertension
- Hypotension
- Diarrhoea
Interactions
- Strong CYP3A4 inducers
- BCRP/OATP substrates
Monitoring
- FBC
- LFTs
- Neurological exam
- BP
Reference: BNF; NICE TA957; SmPC; https://bnf.nice.org.uk/drugs/momelotinib-specialist-drug/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Vancomycin Dosing Calculator · Drug Dosing
- Phenytoin Correction for Albumin / Renal Failure · Drug Dosing
- Local Anaesthetic Maximum Dose Calculator · Drug Dosing
- Tisdale Risk Score for QT Prolongation · Arrhythmia
- Bazett Corrected QT Interval (QTc) Calculator · Arrhythmia
- DAPT Score for Dual Antiplatelet Therapy Duration · Antiplatelet Therapy
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO